MA39294B1 - Polythérapie contre le cancer - Google Patents
Polythérapie contre le cancerInfo
- Publication number
- MA39294B1 MA39294B1 MA39294A MA39294A MA39294B1 MA 39294 B1 MA39294 B1 MA 39294B1 MA 39294 A MA39294 A MA 39294A MA 39294 A MA39294 A MA 39294A MA 39294 B1 MA39294 B1 MA 39294B1
- Authority
- MA
- Morocco
- Prior art keywords
- combytherapy
- against cancer
- fluoro
- benzoimidazol
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne la préparation de médicaments destinés à être utilisés dans le traitement et des méthodes de traitement du cancer du poumon non à petites cellules chez un patient comprenant: de la [5-(4-éthyl-pipérazin-1-ylméthyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-méthyl-3h-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine ou un sel pharmaceutiquement acceptable de celle-ci, en combinaison, tel qu'également décrit dans l'invention, avec un anticorps anti-vegfr2, de préférence, le ramucirumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461944811P | 2014-02-26 | 2014-02-26 | |
PCT/US2015/016529 WO2015130540A1 (fr) | 2014-02-26 | 2015-02-19 | Polythérapie contre le cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39294A1 MA39294A1 (fr) | 2018-06-29 |
MA39294B1 true MA39294B1 (fr) | 2018-12-31 |
Family
ID=52630493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39294A MA39294B1 (fr) | 2014-02-26 | 2015-02-19 | Polythérapie contre le cancer |
Country Status (18)
Country | Link |
---|---|
US (1) | US10238656B2 (fr) |
EP (1) | EP3110444B1 (fr) |
JP (1) | JP5948525B1 (fr) |
KR (1) | KR20160111001A (fr) |
CN (1) | CN106029097A (fr) |
AP (1) | AP2016009402A0 (fr) |
AU (1) | AU2015223359B2 (fr) |
BR (1) | BR112016016880A2 (fr) |
CA (1) | CA2936558A1 (fr) |
EA (1) | EA201691385A1 (fr) |
ES (1) | ES2659424T3 (fr) |
IL (1) | IL246761A0 (fr) |
MA (1) | MA39294B1 (fr) |
MX (1) | MX2016011045A (fr) |
MY (1) | MY176219A (fr) |
SG (1) | SG11201606958YA (fr) |
TW (1) | TWI558399B (fr) |
WO (1) | WO2015130540A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625304A (zh) * | 2014-10-24 | 2016-07-16 | 美國禮來大藥廠 | 泌尿上皮癌之療法 |
WO2017180461A1 (fr) * | 2016-04-15 | 2017-10-19 | Eli Lilly And Company | Polythérapie à base de ramucirumab et d'abémacilib destinée à être utilisée dans le traitement du lymphome à cellules du manteau |
EP3502103B1 (fr) * | 2016-09-09 | 2022-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation |
WO2018093668A1 (fr) * | 2016-11-16 | 2018-05-24 | Eli Lilly And Company | Thérapie pour le cancer colorectal métatastique à l'aide d'anticorps anti-vegfr -2 et anti-vegf-d |
WO2019195569A1 (fr) | 2018-04-05 | 2019-10-10 | Johnson Matthey Public Limited Company | Formes solides d'abémaciclib, leur utilisation et leur préparation |
WO2019195090A1 (fr) * | 2018-04-06 | 2019-10-10 | Eli Lilly And Company | Ramucirumab pour le traitement de cancers chez des patients pédiatriques |
CN113840608B (zh) * | 2019-05-30 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 |
WO2021030843A1 (fr) * | 2019-08-13 | 2021-02-18 | Johnson Matthey Public Limited Company | Formes solides d'abemaciclib, leur utilisation et leur préparation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003213687A1 (en) * | 2002-03-04 | 2003-09-22 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
-
2015
- 2015-02-13 TW TW104105148A patent/TWI558399B/zh not_active IP Right Cessation
- 2015-02-19 CN CN201580010432.3A patent/CN106029097A/zh active Pending
- 2015-02-19 US US15/115,995 patent/US10238656B2/en not_active Expired - Fee Related
- 2015-02-19 EP EP15708638.0A patent/EP3110444B1/fr active Active
- 2015-02-19 MA MA39294A patent/MA39294B1/fr unknown
- 2015-02-19 BR BR112016016880A patent/BR112016016880A2/pt not_active Application Discontinuation
- 2015-02-19 EA EA201691385A patent/EA201691385A1/ru unknown
- 2015-02-19 MY MYPI2016703120A patent/MY176219A/en unknown
- 2015-02-19 AU AU2015223359A patent/AU2015223359B2/en not_active Expired - Fee Related
- 2015-02-19 SG SG11201606958YA patent/SG11201606958YA/en unknown
- 2015-02-19 JP JP2016505628A patent/JP5948525B1/ja not_active Expired - Fee Related
- 2015-02-19 KR KR1020167022971A patent/KR20160111001A/ko active Search and Examination
- 2015-02-19 AP AP2016009402A patent/AP2016009402A0/en unknown
- 2015-02-19 CA CA2936558A patent/CA2936558A1/fr not_active Abandoned
- 2015-02-19 WO PCT/US2015/016529 patent/WO2015130540A1/fr active Application Filing
- 2015-02-19 ES ES15708638.0T patent/ES2659424T3/es active Active
- 2015-02-19 MX MX2016011045A patent/MX2016011045A/es unknown
-
2016
- 2016-07-13 IL IL246761A patent/IL246761A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2659424T3 (es) | 2018-03-15 |
TWI558399B (zh) | 2016-11-21 |
AU2015223359A1 (en) | 2016-08-11 |
TW201542209A (zh) | 2015-11-16 |
AU2015223359B2 (en) | 2017-06-01 |
EP3110444A1 (fr) | 2017-01-04 |
BR112016016880A2 (pt) | 2017-10-03 |
SG11201606958YA (en) | 2016-09-29 |
US20170173013A1 (en) | 2017-06-22 |
MY176219A (en) | 2020-07-24 |
CA2936558A1 (fr) | 2015-09-03 |
AP2016009402A0 (en) | 2016-08-31 |
MX2016011045A (es) | 2016-10-28 |
US10238656B2 (en) | 2019-03-26 |
JP2016521262A (ja) | 2016-07-21 |
EP3110444B1 (fr) | 2018-01-03 |
JP5948525B1 (ja) | 2016-07-06 |
MA39294A1 (fr) | 2018-06-29 |
EA201691385A1 (ru) | 2016-12-30 |
IL246761A0 (en) | 2016-08-31 |
WO2015130540A1 (fr) | 2015-09-03 |
KR20160111001A (ko) | 2016-09-23 |
CN106029097A (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39294A1 (fr) | Polythérapie contre le cancer | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
PH12020500028A1 (en) | Crystalline forms of a bruton`s tyrosine kinase inhibitor | |
MX2019001900A (es) | Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma. | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
SG10201803331PA (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
EP4249076A3 (fr) | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide en tant qu'inhibiteur btk | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MX2013010795A (es) | 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2). | |
WO2013169864A3 (fr) | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie | |
EA201690998A1 (ru) | НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ | |
MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
WO2018033941A3 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
EA201291114A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА |